Drug Prices
Commentary
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Commentary
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Commentary
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Commentary
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary
Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.
Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
Commentary
Learn why drug price controls don't work
The Expected Consequences Of Price Controls
The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Commentary
Learn why drug price controls don't work
Don’t Buy Kamala Harris’ Anti-Price Gouging Plan
That may sound like standard progressive fare. But the means by which she’d try to achieve those goals is a scheme of price controls that could destroy entire sectors of the U.S. economy. Read the full article at Forbes
Commentary
Read the latest on Biden administration's drug price controls
Drug Price Controls Underperform, Unworkable
According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.
Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
Learn why drug price controls don't work
The Expected Consequences Of Price Controls
The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Learn why drug price controls don't work
Don’t Buy Kamala Harris’ Anti-Price Gouging Plan
That may sound like standard progressive fare. But the means by which she’d try to achieve those goals is a scheme of price controls that could destroy entire sectors of the U.S. economy. Read the full article at Forbes
Read the latest on Biden administration's drug price controls
Drug Price Controls Underperform, Unworkable
According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
